Trademagazin > News and articles > Company and Personal News > U.S. Drug Administration approves long-acting antibody AstraZeneca Evusheld (AZD7442)
U.S. Drug Administration approves long-acting antibody AstraZeneca Evusheld (AZD7442)
AstraZeneca’s Evusheld is a long-acting combination of antibodies (tixagevimab and cilgavimab) approved by the U.S. Drug Administration (FDA) for emergency use to prevent COVID-19. The first shipments are expected to be available soon.
Related news
Medicines, yes, but we don’t look for healing on the Internet
In the case of a health complaint they have not…
Read more >BENU and Foglaljorvost.hu signed a cooperation agreement
Hungary’s best-known pharmacy network and the country’s largest healthcare appointment…
Read more >It is being renewed, which is why the Nébih antibiotic use notification system has stopped
Evaluating last year’s experience, Nébih introduces several innovations in the…
Read more >
More related news >
Related news
Auchan has appointed a new product director
From July 1, László Varga will perform the duties of…
Read more >Millions can make decisions about millions with just one move at Tesco
Millions of people once again have millions of forints and…
Read more >Healthy summer nutrition tips with Eisberg
With the arrival of the really hot summer and the…
Read more >